Tesamorelin Guide

Tesamorelin (brand name Egrifta) is a modified GHRH analog that stimulates growth hormone release with superior stability and potency compared to native GHRH. FDA-approved for HIV-associated lipodystrophy, Tesamorelin delivers 15–20% reductions in visceral adipose tissue in clinical trials and is used off-label for body composition optimization.

Tesamorelin is a synthetic analog of endogenous GHRH (growth hormone-releasing hormone) with a trans-3-hexenoic acid chemical modification at the N-terminus. This modification stabilizes the molecule against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), giving Tesamorelin a longer active half-life and more potent pituitary stimulation than native GHRH or Sermorelin.

The FDA approved Tesamorelin as Egrifta in 2010 specifically for reducing excess abdominal visceral fat in HIV-positive adults on antiretroviral therapy (ART). HIV lipodystrophy — characterized by central fat accumulation despite peripheral fat loss — is a major metabolic complication of long-term ART. Tesamorelin addresses this by restoring GH pulsatility and promoting visceral fat lipolysis.

Off-label, Tesamorelin has attracted interest from bodybuilders, biohackers, and anti-aging practitioners for its powerful visceral fat reduction, IGF-1 elevation, and potential cognitive benefits. Research also suggests Tesamorelin may improve cognition in mild cognitive impairment — a finding from National Institute on Aging-funded trials at Vanderbilt University.

Inject into abdominal subcutaneous tissue, rotating sites. Monitor IGF-1 at baseline and every 6 weeks. Target IGF-1: 200–350 ng/mL. Use Shotlee to track daily injections and body composition changes.